Barlow Wealth Partners Inc. Invests $1.38 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

Barlow Wealth Partners Inc. purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 4,127 shares of the company’s stock, valued at approximately $1,383,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. State Street Corp increased its position in shares of Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after purchasing an additional 50,312 shares during the last quarter. Geode Capital Management LLC grew its position in Medpace by 7.6% during the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock valued at $209,885,000 after buying an additional 44,371 shares during the period. Wellington Management Group LLP increased its holdings in Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after buying an additional 109,886 shares during the last quarter. Clearbridge Investments LLC raised its position in Medpace by 55.1% in the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock worth $166,343,000 after acquiring an additional 143,481 shares during the period. Finally, American Capital Management Inc. boosted its stake in Medpace by 2.6% in the third quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock valued at $127,060,000 after acquiring an additional 9,592 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on MEDP shares. Robert W. Baird raised their price target on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a research note on Monday, November 25th. William Blair restated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Redburn Atlantic assumed coverage on Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 price target for the company. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $415.00 to $345.00 in a report on Wednesday, September 25th. Finally, Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Medpace currently has an average rating of “Hold” and a consensus price target of $380.56.

Medpace Price Performance

NASDAQ MEDP opened at $347.52 on Wednesday. The company’s 50 day simple moving average is $340.00 and its two-hundred day simple moving average is $356.52. Medpace Holdings, Inc. has a 1 year low of $286.76 and a 1 year high of $459.77. The stock has a market capitalization of $10.80 billion, a PE ratio of 30.43, a P/E/G ratio of 1.73 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. During the same quarter last year, the company earned $2.22 earnings per share. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. On average, research analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.